CoChat

Effects of the PPARγ agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus

Open access
Nagashima, Kazunori, Lopez, Carlos, Donovan, Daniel, Ngai, Colleen, Fontanez, Nelson, Bensadoun, André, Fruchart-Najib, Jamila, Holleran, Steve, Cohn, Jeffrey S., Ramakrishnan, Rajasekhar, Ginsberg, Henry N. · 2005 · Journal of Clinical Investigation

The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.

Abstract

Elevated plasma levels of VLDL triglycerides (TGs) are characteristic of patients with type 2 diabetes mellitus (T2DM) and are associated with increased production rates (PRs) of VLDL TGs and apoB. Lipoprotein lipase–mediated (LPL-mediated) lipolysis of VLDL TGs may also be reduced in T2DM if the level of LPL is decreased and/or the level of plasma apoC-III, an inhibitor of LPL-mediated lipolysis, is increased. We studied the effects of pioglitazone (Pio), a PPARγ agonist that improves insulin sensitivity, on lipoprotein metabolism in patients with T2DM. Pio treatment reduced TG levels by increasing the fractional clearance rate (FCR) of VLDL TGs from the circulation, without changing direct removal of VLDL particles. This indicated increased lipolysis of VLDL TGs during Pio treatment, a mechanism supported by our finding of increased plasma LPL mass and decreased levels of plasma apoC-III. Lower apoC-III levels were due to reduced apoC-III PRs. We saw no effects of Pio on the PR of either VLDL TG or VLDL apoB. Thus, Pio, a PPARγ agonist, reduced VLDL TG levels by increasing LPL mass and inhibiting apoC-III PR. These 2 changes were associated with an increased FCR of VLDL TGs, almost certainly due to increased LPL-mediated lipolysis.

Overview

Integrity signals

Registry

Crossref · 10.1172/jci200523219

Cites

107 of 107 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Show all 107 references

Research works printed but not linked: 3

  1. 10.1210/jc.87.6.2784 · doi:10.1210/jc.87.6.2784 · Paper page
  2. Diraison, 1998, Am. J. Physiol., 274, E321
  3. Melish, 1980, Am. J. Physiol., 239, E354

Cited by

See all 202

Metadata

Authors
Nagashima, K., Lopez, C., Donovan, D., Ngai, C., Fontanez, N., Bensadoun, A., Fruchart-Najib, J., Holleran, S., Cohn, J. S., Ramakrishnan, R., & Ginsberg, H. N.
Affiliations
  • Columbia University (US)
  • Cornell University (US)
  • Montreal Clinical Research Institute (CA)
Corresponding author
Ginsberg, Henry N.
Venue
Journal of Clinical Investigation
Published
2005-04-01
Volume
115
Issue
5
Pages
1323-1332
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2132525699
Cited by
201
References
104
Citations by year
2025: 5 · 2024: 3 · 2023: 5 · 2022: 1 · 2021: 6 · 2020: 5 · 2019: 8 · 2018: 10 · 2017: 10 · 2016: 10 · 2015: 9 · 2014: 4 · 2013: 5 · 2012: 6
FWCI
15.72
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion)
Funders
  • Takeda Pharmaceuticals North America
  • Deutsches Krebsforschungszentrum
  • National Institutes of Health (RR-00645)
  • National Heart, Lung, and Blood Institute (HL55368)
  • National Center for Research Resources (RR 00645, M01RR000645)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
pioglitazone, PPARγ agonists, type 2 diabetes, lipoprotein metabolism, VLDL triglycerides, lipoprotein lipase, apolipoprotein C-III, triglyceride clearance, lipolysis, insulin sensitivity
MeSH terms
Pioglitazone, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Fatty Acids, Female, Humans, Hypoglycemic Agents, Insulin, Lipoproteins, Cholesterol, HDL, Male, Middle Aged, Triglycerides, Intercellular Signaling Peptides and Proteins, Thiazolidinediones, PPAR gamma, Adiponectin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of the PPARγ agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. https://app.cochat.ai/papers/10.1172/jci200523219
The paper
Nagashima, K., Lopez, C., Donovan, D., Ngai, C., Fontanez, N., Bensadoun, A., Fruchart-Najib, J., Holleran, S., Cohn, J. S., Ramakrishnan, R., & Ginsberg, H. N. (2005). Effects of the PPARγ agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. Journal of Clinical Investigation. https://doi.org/10.1172/jci200523219

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.